Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.
We used shotgun proteomics to identify plasma membrane and lipid raft proteins purified from B cells obtained from mantle cell lymphoma (MCL) patients in leukemic phase. Bioinformatics identified 111 transmembrane proteins, some of which were profiled in primary MCL cases, MCL-derived cell lines, and normal B cells using RT-PCR and Western blotting. Several transmembrane proteins, including CD27, CD70, and CD31 (PECAM-1), were overexpressed when compared with normal B cells. CD70 was up-regulated (>10-fold) in three of five MCL patients along with its cognate receptor CD27, which was up-regulated (4-9-fold) in five of five patients, suggesting that MCL cells may undergo autocrine stimulation via this signaling pathway. Activated calpain I and protein kinase C betaII were also detected in the plasma membranes, suggesting that these proteins are constitutively active in MCL. Protein kinase C betaII has been associated with lipid rafts, and shotgun proteomics/protein profiling revealed that key lipid raft proteins, raftlin (four of five patients) and CSK (C-terminal Src kinase)-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG) (four of four patients) were down-regulated in MCL. Levels of other known lipid raft proteins, such as Lyn kinase and flotillin 1, were similar to normal B cells. However, 5-lipoxygenase (5-LO), a key enzyme in leukotriene biosynthesis, was associated with lipid rafts and was up-regulated approximately 7-fold in MCL compared with normal B cells. Significantly inhibitors of 5-LO activity (AA861) and 5-LO-activating protein (FLAP) (MK886, its activating enzyme) induced apoptosis in MCL cell lines and primary chronic lymphocytic leukemia cells, indicating an important role for the leukotriene biosynthetic pathway in MCL and other B cell malignancies. Thus, using shotgun proteomics and mRNA and protein expression profiling we identified a subset of known and unknown transmembrane proteins with aberrant expression in MCL plasma membranes. These proteins may play a role in the pathology of the disease and are potential therapeutic targets in MCL.
Boyd
Robert S
RS
Medical Research Council, University of Leicester, Leicester, United Kingdom.
Jukes-Jones
Rebekah
R
Walewska
Renata
R
Brown
David
D
Dyer
Martin J S
MJ
Cain
Kelvin
K
D000328:Adult; D000818:Animals; D017209:Apoptosis / Q000502:physiology; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D002462:Cell Membrane / Q000737:chemistry* / Q000378:metabolism; D019295:Computational Biology; D006801:Humans; D007527:Isoenzymes / Q000032:analysis; D016859:Lipoxygenase Inhibitors; D020522:Lymphoma, Mantle-Cell / Q000737:chemistry* / Q000503:physiopathology*; D008297:Male; D021962:Membrane Microdomains / Q000737:chemistry; D008565:Membrane Proteins / Q000032:analysis*; D009363:Neoplasm Proteins / Q000032:analysis*; D040081:Protein Array Analysis / Q000379:methods*; D011493:Protein Kinase C / Q000032:analysis; D064546:Protein Kinase C beta; D040901:Proteomics / Q000379:methods; D015398:Signal Transduction / Q000502:physiology*; D014407:Tumor Cells, Cultured
D007527:Isoenzymes; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D001094:Arachidonate 5-Lipoxygenase; D011493:Protein Kinase C; D064546:Protein Kinase C beta